Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Normal breast-derived epithelial cells with luminal and intrinsic subtype-enriched gene expression document inter-individual differences in their differentiation cascade.

Kumar B, Prasad MS, Bhat-Nakshatri P, Anjanappa M, Kalra M, Marino N, Storniolo AMV, Rao X, Liu S, Wan J, Liu Y, Nakshatri H.

Cancer Res. 2018 Jul 11. pii: canres.0509.2018. doi: 10.1158/0008-5472.CAN-18-0509. [Epub ahead of print]

PMID:
29997232
2.

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.

Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL, Stearns V.

Breast Cancer Res Treat. 2018 May 11. doi: 10.1007/s10549-018-4811-1. [Epub ahead of print]

PMID:
29752687
3.

Metastatic breast cancer patients' expectations and priorities for symptom improvement.

Tometich DB, Mosher CE, Hirsh AT, Rand KL, Johns SA, Matthias MS, Outcalt SD, Schneider BP, Mina L, Storniolo AMV, Newton EV, Miller KD.

Support Care Cancer. 2018 May 7. doi: 10.1007/s00520-018-4244-8. [Epub ahead of print]

PMID:
29736866
4.

Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank.

Oh H, Pfeiffer RM, Falk RT, Horne HN, Xiang J, Pollak M, Brinton LA, Storniolo AMV, Sherman ME, Gierach GL, Figueroa JD.

Int J Cancer. 2018 Aug 1;143(3):496-507. doi: 10.1002/ijc.31333. Epub 2018 Apr 1.

PMID:
29473153
5.

A plasma telomeric cell-free DNA level in unaffected women with BRCA1 or/and BRCA2 mutations: a pilot study.

Dey S, Marino N, Bishop K, Dahlgren PN, Shendre A, Storniolo AM, He C, Tanaka H.

Oncotarget. 2017 Dec 29;9(3):4214-4222. doi: 10.18632/oncotarget.23767. eCollection 2018 Jan 9.

6.

Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trial.

Mosher CE, Secinti E, Li R, Hirsh AT, Bricker J, Miller KD, Schneider B, Storniolo AM, Mina L, Newton EV, Champion VL, Johns SA.

Support Care Cancer. 2018 Jun;26(6):1993-2004. doi: 10.1007/s00520-018-4045-0. Epub 2018 Jan 12.

PMID:
29327085
7.

Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.

Connolly RM, Fackler MJ, Zhang Z, Zhou XC, Goetz MP, Boughey JC, Walsh B, Carpenter JT, Storniolo AM, Watkins SP, Gabrielson EW, Stearns V, Sukumar S.

Breast Cancer Res Treat. 2018 Jan;167(1):107-116. doi: 10.1007/s10549-017-4503-2. Epub 2017 Sep 16.

PMID:
28918548
8.

Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.

Hertz DL, Speth KA, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM.

Breast Cancer Res Treat. 2017 Oct;165(3):659-668. doi: 10.1007/s10549-017-4346-x. Epub 2017 Jun 22.

PMID:
28643023
9.

Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.

Kadakia KC, Kidwell KM, Seewald NJ, Snyder CF, Storniolo AM, Otte JL, Flockhart DA, Hayes DF, Stearns V, Henry NL.

Breast Cancer Res Treat. 2017 Jul;164(2):411-419. doi: 10.1007/s10549-017-4260-2. Epub 2017 Apr 27.

10.

DNA methylation age is elevated in breast tissue of healthy women.

Sehl ME, Henry JE, Storniolo AM, Ganz PA, Horvath S.

Breast Cancer Res Treat. 2017 Jul;164(1):209-219. doi: 10.1007/s10549-017-4218-4. Epub 2017 Mar 31.

11.

Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.

Robarge JD, Desta Z, Nguyen AT, Li L, Hertz D, Rae JM, Hayes DF, Storniolo AM, Stearns V, Flockhart DA, Skaar TC, Henry NL.

Breast Cancer Res Treat. 2017 Feb;161(3):453-461. doi: 10.1007/s10549-016-4077-4. Epub 2016 Dec 9.

12.

Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.

Visvanathan K, Fackler MS, Zhang Z, Lopez-Bujanda ZA, Jeter SC, Sokoll LJ, Garrett-Mayer E, Cope LM, Umbricht CB, Euhus DM, Forero A, Storniolo AM, Nanda R, Lin NU, Carey LA, Ingle JN, Sukumar S, Wolff AC.

J Clin Oncol. 2017 Mar;35(7):751-758. doi: 10.1200/JCO.2015.66.2080. Epub 2016 Nov 21.

13.

Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast.

Bodelon C, Oh H, Chatterjee N, Garcia-Closas M, Palakal M, Sherman ME, Pfeiffer RM, Geller B, Vacek P, Weaver DL, Chicoine R, Papathomas D, Xiang J, Patel DA, Khodr ZG, Linville L, Clare SE, Visscher DW, Mies C, Hewitt SM, Brinton LA, Storniolo AMV, He C, Chanock SJ, Gierach GL, Figueroa JD.

Int J Cancer. 2017 Feb 15;140(4):825-832. doi: 10.1002/ijc.30512. Epub 2016 Nov 18.

14.

Symptom experiences in metastatic breast cancer patients: relationships to activity engagement, value-based living, and psychological inflexibility.

Mosher CE, Tometich DB, Hirsh A, Rand KL, Johns SA, Matthias MS, Outcalt SD, Bricker J, Schneider B, Mina L, Storniolo AM, Newton E, Miller K.

Psychooncology. 2017 Nov;26(11):1944-1951. doi: 10.1002/pon.4283. Epub 2016 Oct 11.

PMID:
27648927
15.

Tissue-specific Co-expression of Long Non-coding and Coding RNAs Associated with Breast Cancer.

Wu W, Wagner EK, Hao Y, Rao X, Dai H, Han J, Chen J, Storniolo AM, Liu Y, He C.

Sci Rep. 2016 Sep 6;6:32731. doi: 10.1038/srep32731.

16.

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.

Hertz DL, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM.

Pharmacogenomics J. 2017 Dec;17(6):521-527. doi: 10.1038/tpj.2016.60. Epub 2016 Aug 23.

17.

West Nile Virus Encephalitis in a Patient with Neuroendocrine Carcinoma.

Deldar R, Thomas D, Storniolo AM.

Case Rep Oncol Med. 2016;2016:9497075. doi: 10.1155/2016/9497075. Epub 2016 Jul 19.

18.

Factors underlying metastatic breast cancer patients' perceptions of symptom importance: a qualitative analysis.

Mosher CE, Daily S, Tometich D, Matthias MS, Outcalt SD, Hirsh A, Johns SA, Rand K, Schneider B, Mina L, Storniolo AM, Newton E, Miller K.

Eur J Cancer Care (Engl). 2018 Jan;27(1). doi: 10.1111/ecc.12540. Epub 2016 Jul 27.

PMID:
27464353
19.

Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclib.

Vuppalanchi R, Saxena R, Storniolo AMV, Chalasani N.

Hepatology. 2017 May;65(5):1762-1764. doi: 10.1002/hep.28720. Epub 2016 Aug 9. No abstract available.

PMID:
27397671
20.

Ages at menarche- and menopause-related genetic variants in relation to terminal duct lobular unit involution in normal breast tissue.

Oh H, Bodelon C, Palakal M, Chatterjee N, Sherman ME, Linville L, Geller BM, Vacek PM, Weaver DL, Chicoine RE, Papathomas D, Patel DA, Xiang J, Clare SE, Visscher DW, Mies C, Hewitt SM, Brinton LA, Storniolo AM, He C, Garcia-Closas M, Chanock SJ, Gierach GL, Figueroa JD.

Breast Cancer Res Treat. 2016 Jul;158(2):341-50. doi: 10.1007/s10549-016-3859-z. Epub 2016 Jun 24.

21.

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.

Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, Desta Z, Rae JM, Otte JL, Carpenter JS, Storniolo AM, Hayes DF, Stearns V, Henry NL.

Oncologist. 2016 May;21(5):539-46. doi: 10.1634/theoncologist.2015-0349. Epub 2016 Mar 23.

22.

Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.

Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, Skaar TC, Dantzer J, Li L, Hangartner TN, Peacock M, Nguyen AT, Rae JM, Desta Z, Philips S, Storniolo AM, Stearns V, Hayes DF, Flockhart DA.

Breast Cancer Res Treat. 2015 Nov;154(2):263-73. doi: 10.1007/s10549-015-3608-8. Epub 2015 Nov 4.

23.

Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.

Santa-Maria CA, Blackford A, Nguyen AT, Skaar TC, Philips S, Oesterreich S, Rae JM, Desta Z, Robarge J, Henry NL, Storniolo AM, Hayes DF, Blumenthal RS, Ouyang P, Post WS, Flockhart DA, Stearns V; Consortium on Breast Cancer Pharmacogenomics (COBRA).

Clin Cancer Res. 2016 Mar 15;22(6):1395-402. doi: 10.1158/1078-0432.CCR-15-1213. Epub 2015 Oct 13.

24.

Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.

Sardesai SD, Storniolo AM.

Womens Health (Lond). 2015 Jun;11(3):281-94. doi: 10.2217/whe.15.9.

PMID:
26102468
25.

TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.

Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ Jr, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC; Translational Breast Cancer Research Consortium (TBCRC).

Clin Cancer Res. 2015 Jun 15;21(12):2722-9. doi: 10.1158/1078-0432.CCR-14-2780. Epub 2015 Mar 16.

26.

Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.

Paoletti C, Li Y, Muñiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson VG, Irvin WJ Jr, Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero-Torres A, Hayes DF; Translational Breast Cancer Research Consortium (TBCRC).

Clin Cancer Res. 2015 Jun 15;21(12):2771-9. doi: 10.1158/1078-0432.CCR-14-2781. Epub 2015 Mar 16.

27.

TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.

Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, Mhlanga J, O JH, Carpenter J, Storniolo AM, Watkins S, Fetting JH, Miller RS, Sideras K, Jeter SC, Walsh B, Powers P, Zorzi J, Boughey JC, Davidson NE, Carey LA, Wolff AC, Khouri N, Gabrielson E, Wahl RL, Stearns V.

J Nucl Med. 2015 Jan;56(1):31-7. doi: 10.2967/jnumed.114.144741. Epub 2014 Dec 4.

28.

Circulating sex hormones and terminal duct lobular unit involution of the normal breast.

Khodr ZG, Sherman ME, Pfeiffer RM, Gierach GL, Brinton LA, Falk RT, Patel DA, Linville LM, Papathomas D, Clare SE, Visscher DW, Mies C, Hewitt SM, Storniolo AM, Rosebrock A, Caban JJ, Figueroa JD.

Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2765-73. doi: 10.1158/1055-9965.EPI-14-0667.

29.

Terminal duct lobular unit involution of the normal breast: implications for breast cancer etiology.

Figueroa JD, Pfeiffer RM, Patel DA, Linville L, Brinton LA, Gierach GL, Yang XR, Papathomas D, Visscher D, Mies C, Degnim AC, Anderson WF, Hewitt S, Khodr ZG, Clare SE, Storniolo AM, Sherman ME.

J Natl Cancer Inst. 2014 Oct 1;106(10). pii: dju286. doi: 10.1093/jnci/dju286. Print 2014 Oct.

30.

Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche.

Perry JR, Day F, Elks CE, Sulem P, Thompson DJ, Ferreira T, He C, Chasman DI, Esko T, Thorleifsson G, Albrecht E, Ang WQ, Corre T, Cousminer DL, Feenstra B, Franceschini N, Ganna A, Johnson AD, Kjellqvist S, Lunetta KL, McMahon G, Nolte IM, Paternoster L, Porcu E, Smith AV, Stolk L, Teumer A, Tšernikova N, Tikkanen E, Ulivi S, Wagner EK, Amin N, Bierut LJ, Byrne EM, Hottenga JJ, Koller DL, Mangino M, Pers TH, Yerges-Armstrong LM, Zhao JH, Andrulis IL, Anton-Culver H, Atsma F, Bandinelli S, Beckmann MW, Benitez J, Blomqvist C, Bojesen SE, Bolla MK, Bonanni B, Brauch H, Brenner H, Buring JE, Chang-Claude J, Chanock S, Chen J, Chenevix-Trench G, Collée JM, Couch FJ, Couper D, Coveillo AD, Cox A, Czene K, D'adamo AP, Smith GD, De Vivo I, Demerath EW, Dennis J, Devilee P, Dieffenbach AK, Dunning AM, Eiriksdottir G, Eriksson JG, Fasching PA, Ferrucci L, Flesch-Janys D, Flyger H, Foroud T, Franke L, Garcia ME, García-Closas M, Geller F, de Geus EE, Giles GG, Gudbjartsson DF, Gudnason V, Guénel P, Guo S, Hall P, Hamann U, Haring R, Hartman CA, Heath AC, Hofman A, Hooning MJ, Hopper JL, Hu FB, Hunter DJ, Karasik D, Kiel DP, Knight JA, Kosma VM, Kutalik Z, Lai S, Lambrechts D, Lindblom A, Mägi R, Magnusson PK, Mannermaa A, Martin NG, Masson G, McArdle PF, McArdle WL, Melbye M, Michailidou K, Mihailov E, Milani L, Milne RL, Nevanlinna H, Neven P, Nohr EA, Oldehinkel AJ, Oostra BA, Palotie A, Peacock M, Pedersen NL, Peterlongo P, Peto J, Pharoah PD, Postma DS, Pouta A, Pylkäs K, Radice P, Ring S, Rivadeneira F, Robino A, Rose LM, Rudolph A, Salomaa V, Sanna S, Schlessinger D, Schmidt MK, Southey MC, Sovio U, Stampfer MJ, Stöckl D, Storniolo AM, Timpson NJ, Tyrer J, Visser JA, Vollenweider P, Völzke H, Waeber G, Waldenberger M, Wallaschofski H, Wang Q, Willemsen G, Winqvist R, Wolffenbuttel BH, Wright MJ; Australian Ovarian Cancer Study; GENICA Network; kConFab; LifeLines Cohort Study; InterAct Consortium; Early Growth Genetics (EGG) Consortium, Boomsma DI, Econs MJ, Khaw KT, Loos RJ, McCarthy MI, Montgomery GW, Rice JP, Streeten EA, Thorsteinsdottir U, van Duijn CM, Alizadeh BZ, Bergmann S, Boerwinkle E, Boyd HA, Crisponi L, Gasparini P, Gieger C, Harris TB, Ingelsson E, Järvelin MR, Kraft P, Lawlor D, Metspalu A, Pennell CE, Ridker PM, Snieder H, Sørensen TI, Spector TD, Strachan DP, Uitterlinden AG, Wareham NJ, Widen E, Zygmunt M, Murray A, Easton DF, Stefansson K, Murabito JM, Ong KK.

Nature. 2014 Oct 2;514(7520):92-97. doi: 10.1038/nature13545. Epub 2014 Jul 23.

31.

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.

Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin NU, Kelly Marcom P, Van Poznak C, Stearns V, Melisko M, Smith JK, Karginova O, Parker J, Berg J, Winer EP, Peterman A, Prat A, Perou CM, Wolff AC, Carey LA.

Breast Cancer Res Treat. 2014 Aug;146(3):557-66. doi: 10.1007/s10549-014-3039-y. Epub 2014 Jul 8.

32.

Depressive rumination and cognitive processes associated with depression in breast cancer patients and their spouses.

Steiner JL, Wagner CD, Bigatti SM, Storniolo AM.

Fam Syst Health. 2014 Dec;32(4):378-88. doi: 10.1037/fsh0000066. Epub 2014 Jul 7.

33.

Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.

Kidwell KM, Harte SE, Hayes DF, Storniolo AM, Carpenter J, Flockhart DA, Stearns V, Clauw DJ, Williams DA, Henry NL.

Cancer. 2014 Aug 15;120(16):2403-11. doi: 10.1002/cncr.28756. Epub 2014 May 6.

34.

Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine.

Force J, Saxena R, Schneider BP, Storniolo AM, Sledge GW Jr, Chalasani N, Vuppalanchi R.

J Clin Oncol. 2016 Jan 20;34(3):e9-12. doi: 10.1200/JCO.2013.49.8543. Epub 2014 Apr 28. No abstract available.

PMID:
24778392
35.

Next-generation transcriptome sequencing of the premenopausal breast epithelium using specimens from a normal human breast tissue bank.

Pardo I, Lillemoe HA, Blosser RJ, Choi M, Sauder CA, Doxey DK, Mathieson T, Hancock BA, Baptiste D, Atale R, Hickenbotham M, Zhu J, Glasscock J, Storniolo AM, Zheng F, Doerge RW, Liu Y, Badve S, Radovich M, Clare SE; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center.

Breast Cancer Res. 2014 Mar 17;16(2):R26. doi: 10.1186/bcr3627.

36.

Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing.

Radovich M, Clare SE, Atale R, Pardo I, Hancock BA, Solzak JP, Kassem N, Mathieson T, Storniolo AM, Rufenbarger C, Lillemoe HA, Blosser RJ, Choi MR, Sauder CA, Doxey D, Henry JE, Hilligoss EE, Sakarya O, Hyland FC, Hickenbotham M, Zhu J, Glasscock J, Badve S, Ivan M, Liu Y, Sledge GW, Schneider BP.

Breast Cancer Res Treat. 2014 Jan;143(1):57-68. doi: 10.1007/s10549-013-2780-y. Epub 2013 Nov 29.

37.

A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.

Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, Macdonald SM, Mahadevan A, Eisenberg E, Ligibel JA, Mayer EL, Moy B, Eichler AF, Winer EP.

Breast Cancer Res Treat. 2013 Nov;142(2):405-14. doi: 10.1007/s10549-013-2754-0. Epub 2013 Nov 7.

PMID:
24197661
38.

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.

Henry NL, Chan HP, Dantzer J, Goswami CP, Li L, Skaar TC, Rae JM, Desta Z, Khouri N, Pinsky R, Oesterreich S, Zhou C, Hadjiiski L, Philips S, Robarge J, Nguyen AT, Storniolo AM, Flockhart DA, Hayes DF, Helvie MA, Stearns V.

Br J Cancer. 2013 Oct 29;109(9):2331-9. doi: 10.1038/bjc.2013.587. Epub 2013 Oct 1.

39.

Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.

Henry NL, Skaar TC, Dantzer J, Li L, Kidwell K, Gersch C, Nguyen AT, Rae JM, Desta Z, Oesterreich S, Philips S, Carpenter JS, Storniolo AM, Stearns V, Hayes DF, Flockhart DA.

Breast Cancer Res Treat. 2013 Apr;138(3):807-16. doi: 10.1007/s10549-013-2504-3. Epub 2013 Apr 2.

40.

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.

Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J.

J Clin Oncol. 2012 Jul 20;30(21):2585-92. doi: 10.1200/JCO.2011.35.6725. Epub 2012 Jun 11.

PMID:
22689807
41.

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP.

J Clin Oncol. 2012 Jul 20;30(21):2615-23. doi: 10.1200/JCO.2010.34.5579. Epub 2012 Jun 4.

42.

Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes.

Philips S, Rae JM, Oesterreich S, Hayes DF, Stearns V, Henry NL, Storniolo AM, Flockhart DA, Skaar TC.

Front Pharmacol. 2012 Mar 30;3:54. doi: 10.3389/fphar.2012.00054. eCollection 2012.

43.

The Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center: a unique resource for defining the "molecular histology" of the breast.

Sherman ME, Figueroa JD, Henry JE, Clare SE, Rufenbarger C, Storniolo AM.

Cancer Prev Res (Phila). 2012 Apr;5(4):528-35. doi: 10.1158/1940-6207.CAPR-11-0234. Epub 2012 Feb 17.

44.

Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.

Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM.

J Clin Oncol. 2012 Mar 20;30(9):936-42. doi: 10.1200/JCO.2011.38.0261. Epub 2012 Feb 13.

45.

Health-related quality of life of african american breast cancer survivors compared with healthy African American women.

Von Ah DM, Russell KM, Carpenter J, Monahan PO, Qianqian Z, Tallman E, Ziner KW, Storniolo AM, Miller KD, Giesler RB, Haase J, Otte J, Champion VL.

Cancer Nurs. 2012 Sep-Oct;35(5):337-46. doi: 10.1097/NCC.0b013e3182393de3.

46.

Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole.

Bell LN, Nguyen AT, Li L, Desta Z, Henry NL, Hayes DF, Wolff AC, Stearns V, Storniolo AM, Flockhart DA; Consortium on Breast Cancer Pharmacogenomics (COBRA).

J Clin Pharmacol. 2012 Dec;52(12):1852-60. doi: 10.1177/0091270011424153. Epub 2011 Dec 15.

47.

Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer.

Bardia A, Arieas ET, Zhang Z, Defilippis A, Tarpinian K, Jeter S, Nguyen A, Henry NL, Flockhart DA, Hayes DF, Hayden J, Storniolo AM, Armstrong DK, Davidson NE, Fetting J, Ouyang P, Wolff AC, Blumenthal RS, Ashen MD, Stearns V.

Breast Cancer Res Treat. 2012 Feb;131(3):907-14. doi: 10.1007/s10549-011-1843-1. Epub 2011 Nov 1.

48.

Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.

Desta Z, Kreutz Y, Nguyen AT, Li L, Skaar T, Kamdem LK, Henry NL, Hayes DF, Storniolo AM, Stearns V, Hoffmann E, Tyndale RF, Flockhart DA.

Clin Pharmacol Ther. 2011 Nov;90(5):693-700. doi: 10.1038/clpt.2011.174. Epub 2011 Oct 5.

49.

Matched and mismatched cognitive appraisals in patients with breast cancer and their partners: implications for psychological distress.

Bigatti SM, Steiner JL, Makinabakan N, Hernandez AM, Johnston E, Storniolo AM.

Psychooncology. 2012 Nov;21(11):1229-36. doi: 10.1002/pon.2028. Epub 2011 Sep 1.

PMID:
21882286
50.

Cytochrome P450 polymorphisms and their relationship with premature ovarian failure in premenopausal women with breast cancer receiving doxorubicin and cyclophosphamide.

Wessels AM, Flockhart DA, Carpenter JS, Radovich M, Li L, Miller KD, Sledge GW, Storniolo AM, Otte JL, Lemler SM, Schneider BP.

Breast J. 2011 Sep-Oct;17(5):536-8. doi: 10.1111/j.1524-4741.2011.01144.x. Epub 2011 Aug 9. No abstract available.

PMID:
21827565

Supplemental Content

Loading ...
Support Center